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Introduction
Dilated cardiomyopathy (DCM) is an important cause of  childhood mortality and is the most common 
indication for heart transplantation in the pediatric population (1–3). Despite efforts to improve patient 
care, pediatric DCM remains a challenging disease with an estimated 50% 5-year transplant-free survival 
(1). Within both the pediatric and adult cohorts, DCM is often associated with mutations in sarcomeric 
and cytoskeletal genes (4). While the genetic basis for pediatric DCM is increasingly recognized (4), few 
therapies have been developed for children suffering from this devastating disease.
Landmark clinical trials have led to the establishment of  medical therapies for adults with dilated and 
ischemic cardiomyopathy (5). Collectively, these therapies target a process termed adverse remodeling, a com-
mon pathway by which the adult heart responds to injury. Pathologically, adverse remodeling is defined by 
cardiomyocyte hypertrophy, myocardial fibrosis, inflammation, and capillary loss (6). While it is reasonable 
to postulate that adult heart failure therapies may be efficacious in children, clinical trials have not supported 
this idea. Despite marked reductions in mortality associated with β-blocker therapy in adult studies, the Pedi-
atric Carvedilol Trial failed to demonstrate improvements in clinical outcomes in children with symptomatic 
heart failure (7, 8). In fact, since the implementation of  digoxin and diuretic therapies decades ago, there has 
been little improvement in outcomes for children with DCM (9). These observations question the effective-
ness of  antiremodeling therapies in children with heart failure and support the idea that, despite a common 
genetic etiology (4), pediatric and adult DCM may represent distinct pathologic entities.
One potential explanation for why antiremodeling therapeutics are not effective in the pediatric pop-
ulation is that adverse remodeling does not govern disease progression in children. Consistent with this 
Pediatric dilated cardiomyopathy (DCM) is the most common indication for heart transplantation 
in children. Despite similar genetic etiologies, medications routinely used in adult heart failure 
patients do not improve outcomes in the pediatric population. The mechanistic basis for these 
observations is unknown. We hypothesized that pediatric and adult DCM comprise distinct 
pathological entities, in that children do not undergo adverse remodeling, the target of adult heart 
failure therapies. To test this hypothesis, we examined LV specimens obtained from pediatric 
and adult donor controls and DCM patients. Consistent with the established pathophysiology of 
adult heart failure, adults with DCM displayed marked cardiomyocyte hypertrophy and myocardial 
fibrosis compared with donor controls. In contrast, pediatric DCM specimens demonstrated 
minimal cardiomyocyte hypertrophy and myocardial fibrosis compared with both age-matched 
controls and adults with DCM. Strikingly, RNA sequencing uncovered divergent gene expression 
profiles in pediatric and adult patients, including enrichment of transcripts associated with adverse 
remodeling and innate immune activation in adult DCM specimens. Collectively, these findings 
reveal that pediatric and adult DCM represent distinct pathological entities, provide a mechanistic 
basis to explain why children fail to respond to adult heart failure therapies, and suggest the need to 
develop new approaches for pediatric DCM.
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hypothesis, some hallmarks of  adverse remodeling including 
β-adrenergic receptor downregulation, and upregulation of  
fetal gene expression appears to occur to a lesser extent in 
pediatric compared with adult heart failure specimens (10). 
Intriguingly, no studies have rigorously determined whether 
adverse remodeling occurs in children or deciphered at what 
age adverse remodeling occurs in adults. Moreover, there is a 
paucity of  information delineating the molecular differences 
that define pediatric and adult heart failure.
To test the hypothesis that adverse remodeling does not 
drive disease progression in pediatric DCM, we obtained car-
diac tissue specimens from the left ventricle (LV) of pediatric 
and adult patients with familial and idiopathic DCM. Using a 
combination of quantitative histology, immunostaining, elec-
tron microscopy, and RNA sequencing, we show that pediatric 
DCM patients do not display pathologic evidence of adverse 
remodeling compared with age-matched donor control speci-
mens. In contrast, adult patients uniformly displayed patholog-
ical evidence of adverse remodeling. Consistent with patholog-
ical evidence of adverse remodeling in adult DCM specimens, 
RNA sequencing revealed that genes associated with sarcomere 
remodeling, inflammation, and fatty acid metabolism were 
enriched in adult compared with pediatric DCM specimens. 
Collectively, these findings indicate that adverse remodeling 
does not occur in children with DCM and suggest that pediatric 
and adult DCM may represent distinct pathological entities.
Results
Study design. To test the hypothesis that adverse remodeling 
does not occur in children with DCM, we obtained LV myo-
cardial specimens from the apex and lateral wall of  nonfailing 
pediatric donor controls (n = 11), pediatric DCM patients (n = 
31), adult nonfailing donor controls (n = 14), and adult DCM 
patients (n = 34) (Table 1 and Supplemental Figure 1; supple-
mental material available online with this article; https://doi.
org/10.1172/jci.insight.94382DS1). To our knowledge, this 
represents the largest collection of  pediatric and adult DCM 
tissue specimens studied to date. Control tissue was obtained from unused donors with normal cardiac func-
tion by echocardiography (Table 2). DCM specimens were obtained from children and adults with advanced-
stage idiopathic or familial DCM at the time of  cardiac transplantation or implantation of  a LV assist device. 
Diseased tissue specimens were further subclassified into age groups of  0–1 years (yrs) (n = 9), 1–10 yrs (n = 
12), 11–18 yrs (n = 10), 19–50 yrs (n = 15), and 51–75 yrs (n = 19). To determine whether adverse remodeling 
occurs in pediatric DCM, we measured cardiomyocyte and sarcomere size, myocardial fibrosis, and capillary 
density in pediatric and adult donor control and DCM specimens. In addition, we performed RNA sequenc-
ing on pediatric and adult DCM specimens to examine gene expression signatures of  adverse remodeling and 
define pathways that differentiate pediatric from adult DCM.
Demographics. Clinical data obtained from pediatric and adult DCM patients demonstrated similar distribu-
tions of male and female subjects and comparable numbers of subjects with idiopathic and familial DCM (Table 
1). Significant differences included the number of left ventricular assist device (LVAD) core and heart explant 
specimens. The pediatric DCM group had a greater number of heart explant specimens, while the adult DCM 
group had a greater number of LVAD core specimens. In addition, disease duration was longer in adult DCM 
subjects, and the frequency of patients with cardiovascular comorbidities — including hypertension, chronic kid-
ney disease, and diabetes — was more prevalent in adult patients with DCM. As expected, adult DCM patients 
were more likely to have received antiremodeling therapies. Echocardiographic data confirmed depressed ejec-
Table 1. Pediatric and adult DCM demographic data
Pediatric DCM Adult DCM P value
n = 31 34
Age in yrs 6.5 51.0 <0.01
Male 21/31 (67.7) 28/34 (82.4) 0.17
Diagnosis
Idiopathic 29/31 (93.5) 30/34 (88.2) 0.47
Familial 2/31 (6.5) 4/34 (11.8) 0.46
Tissue source
LVAD core 6/31 (19.4) 29/34 (85.3) <0.01
Heart explant 25/31 (80.6) 5/34 (14.7) <0.01
Age at diagnosis (yrs) 7.3 46.0 <0.01
Disease duration (yrs) 2.4 5.7 0.02
Hypertension 1/31 (3.2) 15/34 (44.1) <0.01
Diabetes 0/31 (0) 13/34 (38.2) <0.01
Chronic kidney disease 0/31 (0) 6/34 (17.6) <0.01
Medications
β-Blockers 4/8 (50.0) 31/34 (91.1) <0.01
ACEi/ARB 4/8 (50.0) 29/34 (85.3) 0.03
MRAs 2/8 (25.0) 21/34 (61.2) 0.07
Diuretics 3/8 (37.5) 33/34 (97.1) <0.01
Digoxin 3/8 (37.5) 13/34 (38.2) 0.97
Hydralazine 0/8 (0) 7/34 (20.6) 0.16
Nitrates 0/8 (0) 8/34 (23.5) 0.13
Echocardiography
EF (%) [Z score] 22.5 [–7.6] 17.2 0.01
FS (%) [Z score] 11.5 [–14.2] 8.9 0.12
LVDD (mm) [Z score] 5.4 [9.0] 7.0 N/A
LVSD (mm) [Z score] 4.8 [13.7] 6.4 N/A
Percentages displayed in parenthesis. Z scores displayed in brackets for pediatric 
echocardiographic data. EF, ejection fraction; FS, fractional shortening; LVDD, left 
ventricular diastolic dimension (m-mode); LVSD, left ventricular systolic dimension 
(m-mode); CKD, defined as stage 3 or greater chronic kidney disease; ACEi, 
angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; 
MRA, mineralocorticoid receptor antagonist. Pediatric echocardiography data 
represents a limited data set derived from 10 specimens. All other data is derived 
from the complete sample set.
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tion fraction and fractional shortening, as well as increased LV systolic 
and diastolic chamber dimensions in both the adult and pediatric DCM 
groups. LV ejection fraction was slightly lower in the adult DCM cohort. 
Examination of available clinical data obtained from pediatric and adult 
donor controls demonstrated similar sex distribution and ejection frac-
tion. There were a higher proportion of adult donor controls who had 
stroke listed as the cause of brain death (Table 2).
Cardiomyocyte hypertrophy. To examine the extent of  cardiomyo-
cyte hypertrophy, we stained pediatric and adult donor control and 
DCM specimens with rhodamine conjugated wheat germ agglutinin 
(WGA) and measured cardiomyocyte cross-sectional area (Figure 
1A). Measurements were made perpendicular to the long axis of  
each cardiomyocyte. Compared with donor control, pediatric DCM 
specimens did not demonstrate evidence of  increased cardiomyo-
cyte cross-sectional area (271.8 ± 210 vs. 333.5 ± 184 μm2, P = 0.24). 
Consistent with the presence of  cardiomyocyte hypertrophy in adult 
DCM, WGA staining revealed a marked increase in cardiomyocyte 
cross-sectional area in adult DCM samples compared with donor 
controls (416.5 ± 159 vs. 1,058 ± 420 μm2, P < 0.001) (Figure 1B). 
Stratification of  donor controls and DCM specimens by age group 
further demonstrated that increased cardiomyocyte cross-sectional 
area was only evident in adult age groups (Figure 1C). Stratification 
of  pediatric samples by age group (0–1, 1–10, 11–18 yrs) demon-
strated no differences in cardiomyocyte cross-sectional area between 
donor control and pediatric DCM samples. In contrast, adult DCM 
samples displayed increased cardiomyocyte cross-sectional area in 
19–50 and 51–65 yrs age groups. Linear regression analysis further 
confirmed that only adult DCM samples displayed increased cardio-
myocyte cross-sectional area throughout the spectrum of  ages examined (Figure 1D).
To provide additional evidence that cardiomyocyte hypertrophy preferentially occurs in adult and 
not pediatric DCM, we examined cardiomyocyte ultrastructure using transmission electron microscopy 
(Figure 2A). Previous studies have established that pathologic cardiomyocyte hypertrophy is associated 
with increased sarcomere thickness (11, 12). Compared with donor controls, pediatric DCM specimens 
did not demonstrate any changes in sarcomere thickness (0.54 ± 0.04 vs. 0.62 ± 0.14 μm, P = 0.12). In 
contrast, adult DCM specimens displayed increased sarcomere thickness (0.76 ± 0.12 vs. 1.25 ± 0.27 μm, 
P < 0.01) compared with donor controls (Figure 2B).
Myocardial fibrosis. To determine whether pediatric and adult DCM specimens display evidence of  
myocardial fibrosis compared with age-matched controls, we performed Picrosirius red staining, a specific 
marker of  collagen deposition (13). As anticipated, pediatric and adult donor control specimens displayed 
Picrosirius red staining surrounding larger arteries and small blood vessels (perivascular space) and min-
imal staining around individual cardiomyocytes (interstitial space). Pediatric DCM specimens displayed 
similar degrees of  perivascular fibrosis and minimal interstitial fibrosis. In contrast, adult DCM specimens 
Figure 1. Absence of cardiomyocyte hypertrophy in pediatric DCM. (A) 
Wheat germ agglutinin (WGA) staining (red) demonstrating that pediatric 
donor controls and pediatric DCM specimens display similar cardiomyocyte 
cross-sectional area. In contrast, adult DCM patients display increased 
cardiomyocyte cross-sectional area compared with donor controls. Blue, DAPI 
(nuclei). Magnification 400×. (B) Quantification of cardiomyocyte cross-sec-
tional area. (C) Cardiomyocyte cross-sectional area stratified by age, revealing 
that cardiomyocyte cross-sectional area does not differ from donor controls 
across pediatric groups. *P < 0.05 (Mann Whitney U test). (D) Scatter plots 
showing that cardiomyocyte cross-sectional area does not differ as a func-
tion of age in pediatric DCM patients. In contrast, adult DCM patients have 
increased cardiomyocyte cross-sectional area at all ages examined.
4insight.jci.org   https://doi.org/10.1172/jci.insight.94382
R E S E A R C H  A R T I C L E
demonstrated patchy areas of  dense interstitial fibrosis and accentuated 
perivascular fibrosis compared with donor controls (Figure 3A).
Given the presence of  two distinct patterns of  myocardial fibrosis 
(interstitial and perivascular), we chose to employ two methods to 
quantify myocardial fibrosis: i) total Picrosirius red staining, and ii) 
a semiquantitative scoring system to individually quantify the extent 
of  perivascular and interstitial fibrosis (Supplemental Figure 2). To 
minimize potential bias, specimens were scored by two independent 
investigators blinded to sample identity. Quantification of  the per-
centage of  Picrosirius red staining per 20× field revealed no evidence 
of  myocardial fibrosis in pediatric DCM specimens compared with 
pediatric donor controls (1.7 ± 0.7 vs. 2.0 ± 0.3, P = 0.46). In con-
trast, adult DCM specimens displayed evidence of  marked myocar-
dial fibrosis compared with adult donor controls (1.8 ± 0.2 vs. 12.3 ± 
1.1, P < 0.01) (Figure 3B). Quantification of  fibrosis scores revealed no evidence of  interstitial (0.10 
± 0.3 vs. 0.41 ± 0.8, P = 0.08) or perivascular fibrosis (1.1 ± 0.7 vs. 0.52 ± 0.7, P = 0.05) in pediatric 
DCM specimens compared with pediatric donor controls. In contrast, adult DCM specimens displayed 
evidence of  increased interstitial (0.2 ± 0.6 vs. 1.8 ± 0.8, P < 0.01) and perivascular (1.1 ± 0.8 vs. 1.6 ± 
0.7, P = 0.03) fibrosis compared with adult donor controls (Figure 3C). Stratification of  pediatric and 
adult DCM samples by patient age using linear regression and subgroup analyses demonstrated min-
imal total, interstitial, or perivascular fibrosis across the spectrum of  pediatric age groups (0–1, 1–10, 
and 10–18 yrs). In contrast, prominent total, interstitial, and perivascular fibrosis was found in each 
adult subgroup (19–50 and 51–75 yrs) consistent with prior reports (14) (Figure 3, D–F).
Coronary microvasculature. While conflicting data exist regarding whether coronary microvascular density is 
reduced in adult patients with chronic DCM (15–17), it is well appreciated that reductions in myocardial perfu-
sion and flow reserve are strong predictors of poor clinical outcomes (18–22). To date, few studies have examined 
whether coronary microvascular density is altered in pediatric DCM. To clarify whether coronary microvascular 
density is affected in pediatric DCM, we performed CD34 immunostaining on pediatric and adult donor control 
and DCM specimens. Microvascular density was quantified by measuring the percentage of the myocardium that 
displayed CD34 staining, a method we have previously demonstrated to tightly correlate with the number of capil-
laries present per high-power field (23).
Compared with pediatric donor controls, 
coronary microvascular density was increased 
in pediatric DCM (6.1% ± 0.9% vs. 10.9% ± 
5.5%, P < 0.001). In contrast, adult donor 
controls and adult DCM specimens displayed 
similar microvascular density (6.7% ± 1.7% vs. 
6.5% ± 2.0%, P = 0.72) (Figure 4, A and B). 
When CD34 staining was further stratified by 
age groups using either linear regression or sub-
group analyses, we found that coronary micro-
vascular density was increased across the spec-
trum of  pediatric ages. In contrast, coronary 
microvascular density was indistinguishable 
from adult donor controls across each adult 
DCM age group (Figure 4, C and D).
Table 2. Donor control demographic data
Pediatric donor Adult donor P value
n = 11 14
Age in yrs 11.3 50.0 <0.01
Male 7/11 (63.6) 9/14 (64.3) 0.97
EF (%) 54.0 61.7 0.71
Cause of death
Head trauma 4/11 (36.4) 4/14 (28.6) 0.68
Stroke 0/11 (0) 6/14 (42.9) 0.01
Unknown 7/11 (63.6) 4/14 (28.6) 0.09
Percentages displayed in parenthesis. EF, ejection fraction.
 
Figure 2. Sarcomere structure in pediatric and adult DCM. (A) Electron microscopy 
examining sarcomere structure in donor control, pediatric, and adult DCM specimens. 
Compared with donor controls, pediatric DCM patients display no change in sarcomere 
thickness. In contrast, adult DCM patients demonstrate increased sarcomere thickness 
compared with donor controls. (B) Quantification of sarcomere thickness. Each data 
point represents an average of >20 sarcomeres measured from individual patient sam-
ples. P values found with Mann Whitney U test.
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Adverse remodeling, disease duration, and comorbidities. As the duration of  disease significantly differs 
between pediatric and adult DCM, with adult patients having longer periods of  disease (24–26) (Table 
1), we viewed heart failure duration as a confounding variable that may potentially explain why children 
with DCM display less adverse remodeling compared with adult DCM patients. To account for disease 
duration (defined as the period of  time between clinical diagnosis of  heart failure and myocardial specimen 
collection), we divided our adult DCM cohort into three groups: disease duration less than 1 year, disease 
duration 1–5 years, and disease duration greater than 5 years.
Figure 3. Absence of myocardial fibrosis in pediatric DCM. (A) Picrosirius red staining (red) demonstrating that, compared with donor controls, pediatric 
DCM specimens display minimal interstitial or perivascular fibrosis. In contrast, adult DCM patients display increased interstitial and perivascular fibrosis 
compared with donor controls. Magnification 200×. (B) Quantification of percent fibrosis as assessed by total Picrosirius red staining per 20× field in pedi-
atric and adult control and DCM specimens. (C) Quantification of interstitial and perivascular fibrosis scores. (D) Scatter plots showing that the percent 
of Picrosirius staining in pediatric DCM specimens does not differ from donor pediatric controls across the spectrum of child age. In contrast, adult DCM 
patients have increased Picrosirius red staining at all ages examined. (E and F) Total Picrosirius red staining (E) and fibrosis scores (F) stratified by age, 
revealing that interstitial and perivascular fibrosis scores are only increased in adult groups. *P < 0.05 (χ2 test), ***P < 0.05 (compared to pediatric groups).
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Compared with donor controls, adult DCM patients 
who were diagnosed with heart failure for less than 1 year 
displayed similar increases in cardiomyocyte cross-sectional 
area compared with those diagnosed with heart failure for 
1–5 years and greater than 5 years (Figure 5, A and B). While 
there was a trend for increased cardiomyocyte cross-sectional 
area with longer disease durations, these relationships were 
not statistically significant, suggesting that cardiomyocyte 
hypertrophy occurs largely independent of disease duration. 
Similarly, the extent of myocardial fibrosis (Figure 5, C–F) 
and coronary microvascular density (Figure 5, G and H) 
were not influenced by disease duration. Stratification of  
pediatric DCM patients by disease duration revealed no rela-
tionship between disease duration, cardiomyocyte hypertro-
phy, and myocardial fibrosis (Figure 5, I and J).
As the frequency of  hypertension, chronic kidney 
disease, and diabetes was significantly increased in adult 
compared with pediatric DCM patients, we performed 
independent analyses to control for these confounding 
variables. Compared with donor controls, patients with DCM displayed increased cardiomyocyte hyper-
trophy and myocardial fibrosis independent of  the presence of  hypertension, chronic kidney disease, and 
diabetes (Supplemental Figure 3). Collectively, these data signify that disease duration and cardiovascular 
comorbidities, including hypertension, chronic kidney disease, and diabetes, are unlikely to account for the 
observed differences in pathological adverse remodeling between pediatric and adult DCM specimens.
RNA sequencing. To determine whether pediatric and adult DCM represent similar or distinct pathological 
entities at the transcriptomic level, we performed RNA sequencing. Of the LV myocardial tissues included in 
this study, 18 pediatric and 33 adult DCM specimens were of  suitable quality for RNA sequencing and sub-
sequent analysis (Table 3). Of note, we chose not to include donor control samples in our RNA sequencing 
experimental design, as these specimens are obtained from donor hearts that are not suitable for transplanta-
tion due to prolonged ischemic times, profound end organ failure, advanced age, hepatitis C/HIV, and preex-
isting cardiac disease. With respect to this study, we excluded donors with hepatitis C, HIV, and preexisting 
cardiac disease. Importantly, brain death itself  has been demonstrated to increase inflammation within the 
heart (27, 28). Thus, donor specimens obtained from brain-dead individuals are unlikely to represent normal 
cardiac tissue. While these tissues do not appear to demonstrate chronic pathological changes, they likely have 
significant derangements in gene expression and would potentially compromise our RNA sequencing anal-
ysis. For this reason, we have excluded such controls and recognize age as a potential confounding variable.
In support of  the hypothesis that pediatric and adult DCM represent distinct pathological entities, 
principal component analysis demonstrated clear distinctions between pediatric and adult groups (Figure 
6A). Similarly, differential gene expression analysis identified numerous transcripts that were selectively 
regulated in pediatric and adult DCM specimens across the entire spectrum of  transcript abundance 
(Figure 6B). Among the differentially regulated transcripts, 387 mRNAs were upregulated in pediat-
Figure 4. Microvascular alterations in pediatric and adult DCM. 
(A) CD34 immunostaining demonstrating that, compared with 
donor controls, pediatric DCM specimens display increased 
microvascular density. In contrast, adult DCM patients have 
indistinguishable microvascular density compared with donor 
controls. Magnification 200×. (B) Quantification of microvascu-
lar density expressed as the percent of staining per 20× field. 
(C) Scatter plots showing that pediatric DCM patients display 
increased capillary density compared with donor controls across 
the spectrum of child ages. In contrast, capillary density did not 
differ between adult DCM specimens and donor controls at all 
ages examined. (D) CD34 staining stratified by age, revealing 
that microvascular density is increased in all pediatric groups. *P 
< 0.05 (Mann Whitney U test).
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ric DCM and 223 mRNA were upregulated in adult 
DCM by greater than or equal to 2-fold. Likewise, 915 
mRNAs were upregulated in pediatric DCM and 1,018 
mRNAs were upregulated in adult DCM by greater 
than or equal to 1.5-fold (Figure 6C).
Consistent with the observation that adverse remod-
eling selectively occurs in adult DCM, genes previously 
associated with pathological cardiomyocyte hypertrophy 
in humans and animal models (Nppa, Myh7, Mybpc3, 
Actc1, Tpm1, Des, Lmna, Myl3, Mylk3, Pln, Gdf15, 
and Mef2) (29–32) were upregulated in adult compared 
with pediatric DCM. Myh6, a gene that is known to 
decrease with pathological cardiomyocyte hypertrophy, was downregulated in adult compared with pedi-
atric DCM (Figure 6D). In addition to differential regulation of  genes associated with adverse remodeling, 
Gene Ontology (GO) pathway analysis revealed selective regulation of  several other interesting pathways 
(Table 4). Pathways upregulated in adult DCM included those associated with oxidative reduction, fatty acid 
metabolism, response to endogenous stimuli and organic substances, and inflammatory/wounding respons-
es. While differences in substrate utilization and β-adrenergic signaling have been previously described in 
pediatric and adult heart failure (10, 33, 34), distinctions in inflammation have yet to be explored. Among the 
genes associated with inflammation, numerous proinflammatory chemokines, cytokines, danger signals, key 
signal transduction components, and transcription factors were selectively upregulated in adult DCM (Figure 
6E and Supplemental Table 1). Pathways upregulated in pediatric DCM included those previously associated 
with cell adhesion, ion and transmembrane transport, and visual perception. Among the genes associated 
with visual perception, many — to our knowledge — represented novel G-protein coupled receptors with 
similarity to retinal photoreceptors (Supplemental Table 2).
As noted above, we did not include pediatric and adult donor control samples in our analysis. As such, we 
recognized a priori that age may represent a confounding factor. To evaluate the impact of  age on the observed 
differences between pediatric and adult DCM transcript expression, we performed a hierarchical clustering 
analysis based on mRNAs differentially expressed between pediatric and adult DCM groups. Importantly, 
this analysis illustrated that pediatric and adult DCM specimens cluster as two distinct entities rather than as 
a continuum of age. Within each of  the pediatric and adult subgroups, individual specimens are randomly 
distributed by age (Figure 6F). Collectively, these data support the concept that adverse remodeling selectively 
occurs in adult DCM and that pediatric and adult DCM represent distinct pathological entities.
Discussion
This study tested the hypothesis that pediatric and adult DCM represent distinct pathological entities, in that 
children do not undergo adverse remodeling. Collectively, our data support this hypothesis and provide evi-
dence that distinct pathological mechanisms drive the progression of  pediatric and adult DCM. Specifically, 
we demonstrated that adverse remodeling does not uniformly occur in children with DCM, as myocardial 
specimens obtained from patients with pediatric DCM display no significant cardiomyocyte hypertrophy, 
increased sarcomere thickness, or myocardial fibrosis compared with age-matched donor controls. In con-
trast, myocardial specimens obtained from adults with DCM displayed robust increases in cardiomyocyte 
size, sarcomere thickness, and myocardial fibrosis compared with age-matched donor controls. Importantly, 
these findings appear to be irrespective of  patient age across pediatric and adult subgroups, and they appear 
to be independent of  disease duration at least within the adult cohort. Consistent with the pathological data, 
RNA sequencing revealed divergent gene expression profiles between pediatric and adult DCM tissue speci-
mens, with adult specimens displaying marked induction of  transcripts associated with adverse remodeling.
To date, this is the first study to have rigorously evaluated whether adverse remodeling occurs in chil-
dren and to compare myocardial gene expression in a large cohort of  pediatric and adult DCM patients. 
Our results have important clinical implications and may explain several key observations that differentiate 
pediatric from adult DCM. The establishment of  large clinical registries such as the Pediatric Cardiomyop-
athy Registry (PCMR) and execution of  randomized clinical trials has made it possible to define the clinical 
course and outcomes for pediatric DCM (1, 7, 35, 36). Children with DCM display remarkable variability 
in overall outcomes, ranging from complete recovery of  cardiac function (referred to as cardiac recovery) 
Table 3. RNA sequencing analysis
Pediatric DCM adult DCM P value
Total input reads 38,183,302.6 38,260,819.6 0.96
Uniquely mapped reads 32,244,707.4 32,504,594.3 0.84
Uniquely mapped reads (%) 84.5 84.9 0.63
Mismatch rate per base (%) 0.16 0.12 <0.01
Reads mapped to multiple loci 4,832,155.6 4,961,119.8 0.76
Reads mapped to multiple loci (%) 12.5 12.9 0.64
Unmapped reads (%) 2.1 1.4 0.07
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to disease progression and need for cardiac transplantation 
or mechanical circulatory support (37). Interestingly, a com-
peting-outcomes analysis demonstrated that, within 2 years 
of  diagnosis, children with DCM will experience sustained 
disease stabilization, cardiac recovery, or disease progres-
sion (cardiac mortality or transplantation) (26). The mech-
anisms that orchestrate why individual children experience 
each of  these outcomes remain poorly defined.
One of  the most apparent distinctions between pedi-
atric and adult DCM is the repeated observation that 
antiremodeling medications routinely used to treat adult 
heart failure patients do not significantly improve out-
comes in children. The Pediatric Carvedilol Trial failed 
to demonstrate significant improvements in either clinical 
outcomes or echocardiographic parameters in children 
with DCM (7). In addition, registry data revealed that 
children with DCM treated with angiotensin converting 
enzyme (ACE) inhibitors or β-blockers had indistinguish-
able survival compared with those only receiving digoxin- and diuretic-based regimens (1, 9). Our 
data provides a mechanistic rationale for why children do not respond to adult heart failure thera-
peutics and strongly suggest that prognostic and therapeutics strategies routinely used in adults may 
have limited clinical utility in the pediatric population. These results are consistent with prior studies 
showing that hallmarks of  adverse remodeling, including β-adrenergic receptor downregulation, fetal 
gene expression, and fibrosis, occur to a lesser extent in pediatric DCM (10, 38). In addition, the lack 
of  myocardial fibrosis in pediatric patients with DCM may provide an explanation as to why sudden 
death is more prevalent in adult compared with pediatric DCM patients (39).
Disease duration represented a potential important variable that differed between the pediatric and 
adult DCM cases. Controlling for disease duration in our adult cohort demonstrated that increased disease 
duration in adult DCM did not constitute the primary reason why cardiomyocyte hypertrophy and myocar-
Figure 5. Disease duration does not influence pathological evi-
dence of adverse remodeling in adult and pediatric DCM. (A) Quan-
tification of cardiomyocyte cross-sectional area stratified by disease 
duration reveals that patients diagnosed with heart failure < 1 year, 
1–5 years, or < 5 years prior to tissue procurement displayed marked 
cardiomyocyte hypertrophy compared with donor controls. No sig-
nificant differences were evident between disease duration groups. 
(B) Linear regression analysis describing the relationship between 
cardiomyocyte cross-sectional area and disease duration. (C) Quan-
tification of total Picrosirius red staining stratified by disease dura-
tion reveals that patients diagnosed with heart failure < 1 year, 1–5 
years, or < 5 years prior to tissue procurement displayed increased 
fibrosis compared with donor controls. (D) Linear regression analysis 
describing the relationship between total Picrosirius red staining 
and disease duration. (E and F) Quantification of interstitial and 
perivascular fibrosis stratified by disease duration demonstrates 
that myocardial fibrosis occurs independent of disease duration. 
No significant differences were evident between disease duration 
groups. (G and H) Quantification of CD34 staining stratified by dis-
ease duration demonstrates no relationship between microvascular 
density and disease duration. (I and J) Quantification of myocardial 
fibrosis (I) and cardiomyocyte cross-sectional area (J) stratified by 
disease duration reveals that children diagnosed with heart failure < 
1 year or < 1 year prior to tissue procurement displayed no indistin-
guishable levels of myocardial fibrosis and cardiomyocyte hypertro-
phy compared with donor controls. No significant differences were 
evident between disease duration groups. *P < 0.05 compared with 
donor control. Mann Whitney U test (A, C, G) or χ2 test (E and F).
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dial fibrosis occurred at dramatically higher frequency in adult DCM patients. However, there was a trend 
(P = 0.09) between increased disease duration and greater extents of  cardiomyocyte hypertrophy in adult 
DCM. Examination of  disease duration in the pediatric DCM groups revealed no significant relationship 
between disease duration, cardiomyocyte hypertrophy, or adverse remodeling. Of  note, statistically nonsig-
nificant trends suggested that cardiomyocyte hypertrophy may be exaggerated by hypertension and chronic 
kidney disease. These data suggest that, within the adult DCM cohort, disease duration, hypertension, and 
chronic kidney disease may contribute to the extent of  adverse remodeling. Importantly, these relationships 
were limited by sample size and should be viewed as speculative.
The apparent absence of  adverse remodeling in pediatric DCM raises the question of  what dis-
tinct disease mechanisms drive heart failure progression in children. In adult patients with ischemic and 
dilated cardiomyopathies, it is clear that heart failure initiation and progression are driven by separate 
pathophysiological processes (i.e., myocardial infarction or genetic mutations and adverse remodeling, 
respectively) (40, 41). Whether the failing pediatric heart follows a similar paradigm and undergoes a 
distinct remodeling program or whether disease progression is simply governed by the underlying cause 
of  the cardiomyopathy is unclear. Future studies clarifying these mechanisms will be essential to guide 
effective therapeutic strategies for children with DCM.
The capacity to recover cardiac function (i.e., cardiac recovery), represents an important difference 
between pediatric and adult DCM. Approximately 20% of  children diagnosed with pediatric DCM will 
spontaneously and completely recover LV systolic function over a two-year follow-up period (37). In con-
trast, cardiac recovery is a relatively infrequent outcome in the adult patients with chronic heart failure (42, 
43). The observation that cardiac recovery occurs spontaneously in the pediatric population was further 
demonstrated in the Pediatric Carvedilol Trial, where children in both the placebo and carvedilol groups 
displayed improved LV systolic function through the course of  the study (7). These observations suggest 
that cardiac recovery represents an achievable outcome and a potential target for pediatric heart failure 
therapeutics. Consistent with this concept, previous reports have indicated that patients who experience 
cardiac recovery have improved quality of  life and long-term survival (44).
The underlying mechanisms that dictate cardiac recovery and explain why children have a greater 
capacity for cardiac recovery compared with adults are poorly defined. The absence of  adverse remodeling 
in pediatric DCM patients may represent one such explanation. Indeed, we and others have previously 
demonstrated that, in a mouse model of  pediatric cardiac recovery, adverse remodeling only occurs in 
animals that lack the capacity to replace lost cardiomyocytes and expand the coronary vasculature (45–47). 
Consistent with these animal models, it has previously been demonstrated that children have a greater 
capacity for cardiomyocyte proliferation compared with adults (48), and in this study, we showed that cor-
onary microvascular expansion occurs in pediatric but not adult DCM.
The molecular basis explaining why pediatric and adult DCM have differential capacity for cardiac recovery 
and distinct pathologies (i.e., adverse remodeling) are poorly defined. Using RNA sequencing, we compared the 
transcriptomes of 18 pediatric and 33 adult DCM patients, the largest study reported to date, to our knowledge. 
Strikingly, more than 1,900 mRNA transcripts were differentially regulated between pediatric and adult DCM 
using an FDR < 0.05 and fold change > 1.5. In addition to differential expression of transcripts associated with 
Table 4. GO pathway analysis
Increased expression in adult DCM, n = 1,018 genes P value Fold enrichment
GO:0055114: oxidation reduction 67 2.40 × 10–7 1.94
GO:0009719: response to endogenous stimulus 47 1.35 × 10–6 2.15
GO:0010033: response to organic substance 70 2.10 × 10–6 1.80
GO:0009611: response to wounding 51 8.05 × 10–5 1.78
GO:0006954: inflammatory response 35 1.66 × 10–4 2.00
GO:0006631: fatty acid metabolic process 25 1.71 × 10–4 2.33
Increased expression in pediatric DCM, n = 915 genes P value Fold Enrichment
GO:0006811: ion transport 59 1.33 × 10–8 2.22
GO:0007155: cell adhesion 54 5.56 × 10–8 2.23
GO:0055085: transmembrane transport 43 2.77 × 10–6 2.18
GO:0007601: visual perception 19 5.06 × 10–4 2.54
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adverse remodeling, pathway analysis revealed that adult specimens displayed marked induction of transcripts 
associated with innate immune system activation, fatty acid and oxidative metabolism, and metabolite signaling. 
These data confirm the importance of metabolism and substrate utilization in adult heart failure and signify the 
potential relevance of innate immune activation in the pathogenesis of adult DCM.
A wealth of  literature has established that the failing adult heart displays important restrictions in 
substrate availability and utilization (49). Under resting conditions, the healthy adult heart metabolizes a 
diverse array of  substrates including glucose, fatty acids, amino acids, and ketones. When the healthy heart 
Figure 6. RNA sequencing analysis. (A) Principal component analysis demonstrating segregation of pediatric and adult DCM samples. (B) Bland-Altman 
(MA) plot depicting the relationship between differential gene expression and transcript abundance in pediatric and adult DCM samples. (C) Differential gene 
expression analysis highlighting the number of mRNA transcripts that are differentially expressed by 1.5- and 2-fold in pediatric and adult DCM samples. (D 
and E) mRNA transcripts associated with sarcomere remodeling (D) and inflammation (E) are differentially regulated in pediatric and adult DCM. (F) Hierarchi-
cal clustering analysis illustrating that pediatric and adult DCM samples cluster as two distinct entities rather than as a continuum of age. Ped, pediatric.
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is faced with periods of  stress, glucose and, to a lesser extent, free fatty acid utilization increases (50). In 
contrast, metabolic derangements in the chronically failing adult heart result in restricted substrate utiliza-
tion. While fatty acid oxidation is maintained in early stages of  adult heart failure (51, 52), reductions in 
fatty acid uptake and utilization occur during the course of  disease progression (53). Consistent with the 
loss of  metabolic flexibility, the chronically failing adult heart is unable to augment glucose uptake during 
periods of  stress (54, 55). These metabolic perturbations are thought to be due to a complex interplay of  
mechanisms, including insulin resistance, mitochondrial dysfunction, and neurohormonal activation (56, 
57). Interestingly, increased sympathetic outflow and plasma norepinephrine levels in adult heart failure 
are associated with the development of  insulin resistance, circulating fatty acids, and impaired glucose 
utilization linking metabolic derangements to adverse remodeling (58). With the exception of  differing 
sensitivities to ischemia (33), little is known regarding metabolism in the pediatric heart.
Previous studies have established that innate immune activation is associated with the onset and progres-
sion of  heart failure in adult patients. Circulating levels of  TNFα, IL1β, and IL6 are elevated in adults with 
chronic heart failure and are predictive of  poor prognosis (59–63). While the precise mechanisms that orches-
trate proinflammatory responses in adult heart failure are not completely understood, it is clear that inhibition 
of  inflammatory cytokine signaling may be beneficial (64). Blockade of  IL1β signaling improves LV systolic 
function and suppresses components of  adverse remodeling, including cardiomyocyte hypertrophy and myo-
cardial fibrosis (65–70). As such, IL1β antagonists are under clinical investigation as novel therapeutics for 
adults with acute myocardial infarction (MI) and heart failure (71, 72). While reduced inflammatory gene 
expression in pediatric DCM may suggest that antiinflammatory approaches may be less efficacious in chil-
dren, future studies will be required to directly test the feasibility of  IL1β blockade in pediatric heart failure.
In comparison with adult DCM, pediatric specimens displayed induction of  transcripts associ-
ated with cell adhesion, ion and transmembrane transport, and a variety of  novel G-protein coupled 
receptors similar to those utilized for visual perception. Based on the current literature, the functional 
relevance of  these genes and pathways with respect to the pathophysiology of  pediatric heart failure is 
not immediately apparent. Whether these gene expression changes represent adaptive or maladaptive 
responses to pediatric DCM remains unclear but will undoubtedly be the subject of  future investiga-
tion in suitable preclinical models.
Limitations. While this study represents, to our knowledge, the largest cohort of  pediatric and adult 
DCM specimens studied to date, sample size remains an important limitation. Although the overall 
pediatric and adult populations were of  sufficient size for comparative analyses, secondary subgroup 
analyses (i.e., age subgroups) were limited by sample size and, as such, should be interpreted with cau-
tion. In addition, this analysis is limited by the availability of  clinical data, including genetic analyses 
identifying causative variants. Thus, covariates in addition to patient age may contribute to differences 
in adverse remodeling and gene expression. For example, in the absence of  genetic data, it is not possi-
ble to directly compare pediatric and adult DCM samples harboring similar mutations. However, given 
the robust differences observed across pediatric and adult cohorts, it is likely patient age (pediatric vs. 
adult) represents a major component. The omission of  control specimens represents an inherent lim-
itation of  our RNA sequencing analysis. As control specimens are typically obtained from brain-dead 
donors that are not suitable for transplantation due to preexisting cardiac disease, hepatitis C/HIV, 
prolonged ischemic times, and end organ failure, they do not represent normal cardiac tissue. While 
these tissues do not appear to demonstrate chronic pathological changes, they likely have significant 
derangements in gene expression, and that would likely confound our RNA sequencing analysis. For 
this reason, we excluded donor controls from the RNA sequencing analysis and recognize age as a 
confounding variable. Lastly, it is currently unknown whether our findings extend to other etiologies 
of  pediatric heart failure, including hypertrophic cardiomyopathy, chemotherapy-induced cardiomy-
opathy, or even single-ventricle myocardial dysfunction. Future studies should investigate whether and 
to what extent adverse remodeling occurs in these disease settings.
Conclusions. Collectively, our findings support the concept that pediatric and adult DCM represent 
distinct pathological entities and provide a mechanistic basis to explain why children with DCM fail to 
respond to antiremodeling medications commonly used in adult heart failure patients. Together, these 
observations support a shift in clinical management of  pediatric DCM and suggest that it may be appropri-
ate to revise therapeutic approaches for children stricken with this devastating disease.
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Methods
Pathologic specimens. Cardiac tissue specimens were obtained from pediatric and adult patients with idio-
pathic and familial DCM undergoing LVAD implantation or cardiac transplantation. Patients with second-
ary causes of  DCM, including cardiac amyloidosis, cardiac sarcoidosis, viral myocarditis, giant cell myo-
carditis, peripartum cardiomyopathy, and complex congenital heart disease, were excluded from this study. 
In addition, children who were classified as having neuromuscular disease–related cardiomyopathy, meta-
bolic/mitochondrial disorder, or myocarditis on the basis of  clinical presentation or biopsy were excluded. 
Adults with ischemic cardiomyopathy, chemotherapy-associated cardiomyopathy, and alcohol-induced 
cardiomyopathy were excluded. Tissues consisted of  transmural specimens obtained from the apical or 
lateral wall of  the LV. Cardiac tissue specimens (donor control and DCM) were either immediately flash 
frozen or fixed in 10% formalin upon collection to preserve tissue integrity. Pediatric DCM specimens were 
acquired from the PCMR tissue repository and the Washington University Translational Cardiovascular 
Biobank and Repository (TCBR). Pediatric donor control specimens were obtained from the University of  
Colorado (Boulder, Colorado, USA). Control specimens acquired from brain-dead patients with normal 
LV systolic function and LV dimensions by echocardiography that were deemed not suitable for cardiac 
transplantation. Adult donor control and DCM specimens were obtained from the TCBR. The PCMR 
repository and the TCBR tissue bank diagnostic criteria for DCM was based on echocardiographic mea-
surements related to LV enlargement and depressed systolic function, pathologic findings at autopsy, expla-
nation or biopsy, and clinical evidence by the diagnosing cardiologist.
Cardiomyocyte hypertrophy. To evaluate for cardiomyocyte hypertrophy, rhodamine-conjugated WGA 
staining was used to demarcate plasma membrane boundaries on tissue sections of  cardiomyocytes in 
cross section. Myocardial specimens were fixed in 10% formalin for 72 hours. Tissues were embedded in 
paraffin and 4-μm sections obtained using a Leica microtome. Paraffin sections were dewaxed with xylene, 
rehydrated, blocked with 1% BSA, and stained rhodamine-conjugated WGA (Vector Laboratories, 1:200). 
Sections were then washed and mounted in Vectashield with DAPI (Vector Laboratories). At least 5 images 
per specimen were obtained on a Zeiss Confocal Microscope at 20× magnification. Serial sections were 
used to identify cardiomyocytes that were oriented perpendicular to the long axis. Cross-sectional area was 
measured using AxioVision software. For each individual, at least two separate myocardial specimens were 
examined and >20 cardiomyocytes per specimen were measured by two observers blinded to the experi-
mental group. The criteria for cardiomyocytes to be included in the analysis consisted of  cross-sectional 
morphology and the presence of  DAPI-stained nuclear material.
Myocardial fibrosis. To evaluate for myocardial fibrosis, we stained for collagen using Picrosirius red 
(Thermo Fisher Scientific). Paraffin-embedded sections were dewaxed in xylene, rehydrated, stained with 
Picrosirius red for 20 minutes, washed in acid water, dehydrated, and mounted in a xylene-based media 
(Cytoseal, Thermo Fisher Scientific). For each individual, multiple fields from at least two separate myo-
cardial specimens were included in the final analysis. A scoring system was utilized to measure the degrees 
of  perivascular fibrosis and interstitial fibrosis to allow discrimination of  distinct patterns of  fibrosis. Scor-
ing was performed by two observers blinded to the experimental group, with results averaged for each 
patient. The scoring protocol is outlined in Supplemental Figure 1.
Capillary staining. To measure coronary microvascular density, we performed IHC with an anti-CD34 
(QBEnd/10, Abcam) antibody (catalog ab8536). The CD34 antibody was chosen due to previous reports 
demonstrating excellent signal intensity across a variety of  specimens (23). Paraffin-embedded sections were 
dewaxed in xylene, rehydrated, blocked in 1% BSA, and stained with anti-CD34 (1:400) antibody overnight. 
The primary antibody was detected using a biotin conjugated anti–mouse secondary antibody (Vector Lab-
oratories) in conjunction with streptavidin HRP (ABC Elite, Vector Laboratories) and DAB reagent (Vector 
Laboratories). Slides were then dehydrated and mounted in a xylene-based media (Cytoseal). Photographs 
were acquired at 20× on a Zeiss Axioskope system. For each individual, at least two separate myocardial 
specimens were included. Microvascular density was measured from at least 2–3 slides per specimen using 
Image J software as previously described (23). Using this methodology, we previously demonstrated that auto-
mated measurement of  the percent area stained was highly correlated with manual counting of  the number 
of  capillaries per field. The averaged values from > 5 images per individual were included in the final analysis.
Electron microscopy. Cardiac specimens (2 mm2) were fixed in a mixture of  2.5% glutaraldehyde and 
2% paraformaldehyde in 0.15 M cacodylate buffer at pH 7.4 containing 2 mM calcium chloride at 4˚C 
overnight. Sample were rinsed in 0.15 M cacodylate buffer 3× for 10 minutes each and subjected to a 
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secondary fixation step for 1 hour in 1% osmium tetroxide containing 1.5% potassium ferrocyanide 
in cacodylate buffer on ice. Following fixation, samples were then washed in ultrapure water 3× for 
10 minutes each and en bloc stained for 1 hour with 2% aqueous uranyl acetate. All reagents listed in 
previous sentences are from Sigma-Aldrich. After staining was complete, samples were briefly washed 
in ultrapure water, dehydrated in a graded acetone series (50%, 70%, 90%, 100% ×2) for 10 minutes 
in each step, infiltrated with microwave assistance (Pelco BioWave Pro) into LX112 resin, embedded 
in silicone molds, and cured in an oven at 60˚C for 48 hours. Once the resin was cured, each block 
was trimmed and faced using a diamond trim tool (Leica EM TRIM2). Longitudinal sections (70 nm) 
were obtained and imaged on a FE-SEM (Zeiss Crossbeam 540) using the aSTEM detector. The SEM 
was operated at 28 KeV with a probe current of  0.9 nA, and the STEM detector was operated with 
the annular rings inverted for additional sample contrast. Large sample areas were imaged at a reso-
lution of  4,096 × 3,072 pixels, with a pixel size of  5.582 nm. Sarcomere thickness was measured in 
two samples per specimen by individuals blinded to sample identity. Greater than 20 sarcomeres were 
measured from each individual patient sample, and the average sarcomere thickness was calculated.
RNA sequencing. Total RNA was harvested from transmural pediatric and adult DCM samples 
(200–400 mg) by disrupting samples in Trizol (Thermo Fisher Scientific) using the Qiagen TissueLyser 
homogenizer with stainless steel beads. Following phenol chloroform extraction, RNA was purified 
using the Ambion Purelink miniprep kit. RNA integrity was quantified on an Agilent Bioanalyzer, 
and samples with RNA Integrity Number > 8 were utilized for RNA sequencing. Ribosomal RNAs 
were depleted with Ribo-Zero, cDNA libraries were generated, and samples were sequenced (1 × 50 
bp reads) on an Illumina HiSeq 3000 instrument. Sequence alignment, normalization, and differential 
expression analysis was carried out in the Genome Technology Access Center at Washington Univer-
sity using Limma-Voom software. PCA and Hierarchical cluster analysis was performed in Partek. 
GO Pathway analysis was performed using DAVID. Transcripts with > 10 reads in 50% of  samples 
demonstrating a fold change > 1.5-fold at an FDR < 0.05 were included in the pathway analysis. Raw 
data was deposited in the NCBI sequence reads archive (SRA, SRP108128).
Statistics. Primary comparisons were made between control and DCM groups for each age group. Fish-
er’s exact and Mann-Whitney U tests with appropriate Bonferroni correction were used to identify statis-
tically significant differences between groups. Data are presented as either dot plots or bar graphs, with all 
data points displayed (mean ± SD).
Study approval. This study was approved by the Washington University in St. Louis IRB (protocal num-
ber 201305086) . All subjects provided informed consent prior to sample collection, and the experiments 
were performed in accordance with the approved study protocol.
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